OS Therapies Incorporated OSTX
0.74 USD +0.06 (+9.42%)
Regular-session close
0.75 +0.01 +1.02%
After hours · Nov 17, 7:40 PM ET
0.6497 Day range 0.7699
0.58 52-week range 2.25
- YTD
- -46.80%
- 1 year
- -56.44%
News
benzinga.com OS Therapies Says FDA's Shelving Of Commissioner's National Priority Voucher Has No Impact On Its Rare Pediatric Disease PRV Prospects OST-HER2 remains eligible for Priority Review Voucher ("PRV") if approved by the U.S. Food and Drug Administration's ("FDA") on or before September 30, 2029Company continues to benefit from its UK
newsfilecorp.com OS Therapies Announces Shelving of U.S. FDA Commissioner's National Priority Voucher Has No Impact on the Company OST-HER2 remains eligible for Priority Review Voucher ("PRV") if approved by the U.S. Food and Drug Administration's ("FDA") on or before September 30, 2029 Company continues to benefit from its UK…benzinga.com OS Therapies Initiates CMAA Process With UK MHRA For Herlystic In Prevention Or Delay Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma; Expects To Complete CMAA Process Later In Q4 Of 2026 US Based Clinical Stage Oncology Company Begins Critical Step Following Successful September 2026 Scientific Advice MeetingSubmission expected to be accepted in the fourth quarter of 2026Potential…
newsfilecorp.com OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma US Based Clinical Stage Oncology Company Begins Critical Step Following Successful September 2026 Scientific Advice Meeting Submission expected to be accepted in the fourth quarter of 2026 Potential…
